YWHAQ Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">YWHAQ Protein</th>
</tr>
<tr>
<td class="label">Client</td>
<td>Binding Site</td>
</tr>
<tr>
<td class="label">BAD</td>
<td>Ser112, Ser136</td>
</tr>
<tr>
<td class="label">BAX</td>
<td>Ser184</td>
</tr>
<tr>
<td class="label">RAF1</td>
<td>Multiple sites</td>
</tr>
<tr>
<td class="label">TRADD</td>
<td>Various</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Multiple sites</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Peptide inhibitors</td>
<td>R18 derivatives</td>
</tr>
<tr>
<td class="label">Stabilizers</td>
<td>Fusicoccin</td>
</tr>
<tr>
<td class="label">Dissociators</td>
<td>BV02</td>
</tr>
<tr>
<td class="label">Allosteric</td>
<td>Not identified</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">α-Synuclein</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Kinase regulation</td>
</tr>
<tr>
<td class="label">Parkin</td>
<td>E3 ligase regulation</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Phospho-dependent</td>
</tr>
<tr>
<td class="label">BAD</td>
<td>Pro-apoptotic sequestration</td>
</tr>
<tr>
<td class="label">BAX</td>
<td>Mitochondrial apoptosis</td>
</tr>
<tr>
<td class="label">RAF1</td>
<td>MAPK signaling</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
YWHAQ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Theta), also known as 14-3-3 theta or 14-3-3τ, is a member of the highly conserved 14-3-3 family of adapter proteins that regulate over 2,000 client proteins through phosphorylation-dependent interactions[@aitken2006][@gardino2009]. The 14-3-3 family consists of seven isoforms (β, ε, γ, η, σ, θ, ζ) that play essential roles in signal transduction, [cell cycle regulation](/entities/cell-cycle), [apoptosis](/entities/apoptosis), [metabolism](/entities/metabolism), and [stress responses](/entities/oxidative-stress)[@morrison2009]. In the nervous system, 14-3-3 proteins have emerged as critical modulators of neurodegeneration, with particular relevance to [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis)[@wang2014][@xing2020].
Protein Structure
Primary Structure
YWHAQ is a 245-amino acid protein with a molecular weight of approximately 28 kDa. The protein lacks intrinsic enzymatic activity and functions purely as an adapter/scaffold[@aitken2006].
Three-Dimensional Architecture
The 14-3-3 proteins share a highly conserved structure[@gardino2009][@obsilova2021]:
- Nine Helices (αA-αI): Form a boomerang-shaped amphipathic dimer
- Phosphopeptide-binding Groove: Formed by the dimer interface, recognizing phosphorylated serine/threonine motifs
- Client Protein Interaction Surface: Extended surface area for diverse client interactions
Dimerization
14-3-3 proteins function as obligatory dimers, with each monomer capable of binding independent client proteins[@gardino2009]:
- Parallel dimer arrangement: Creates a phosphopeptide-binding groove
- Allosteric regulation: Client binding can influence the opposite monomer
- Isoform mixing: Can form heterodimers between different 14-3-3 isoforms
Molecular Mechanisms
Phosphorylation-Dependent Substrate Recognition
YWHAQ binds to client proteins containing phosphorylated serine/threonine residues within specific motifs[@aitken2006][@yaffe1997]:
- Mode I: RSXpS/pT (Arg/Ser-X-pSer/pThr)
- Mode II: RXXXpS/pTXP (Arg-any-any-any-pSer/pThr-any-Pro)
- Mode III: pS/pT within specific contexts
Key Signaling Pathways Regulated by YWHAQ
MAPK/ERK Signaling
- Binds to and regulates BRAF, RAF1, and MEK1/2
- Modulates MAPK cascade output
- Influences neuronal differentiation and survival[@zhang2010]
PI3K/Akt Signaling
- Interacts with Akt and PDK1
- Regulates AKT membrane localization
- Influences cell survival decisions
Cell Cycle Control
- Binds to CDK-cyclin complexes
- Regulates G1/S and G2/M transitions
- Controls entry into mitosis[@luk2010]
Apoptosis Regulation
- Sequesters pro-apoptotic proteins BAD and BAX
- Prevents mitochondrial permeabilization
- Promotes cell survival under stress[@masters2010]
Client Protein Examples
Role in Neurodegeneration
Parkinson's Disease
YWHAQ has emerged as a particularly important player in [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis[@wang2014][@dumitriu2016][@wong2015]:
Lewy Body Pathology
- 14-3-3 proteins are major components of [Lewy bodies](/entities/lewy-bodies)
- YWHAQ co-aggregates with α-synuclein in PD brains
- May represent a protective sequestration mechanism
LRRK2 Interaction
- YWHAQ binds to pathogenic LRRK2 mutations (G2019S, R1441C/G/H)
- Modulates LRRK2 kinase activity and cellular toxicity
- Potential therapeutic target for LRRK2-linked PD
Dopaminergic Neuron Survival
- Protects against MPTP-induced parkinsonism
- Binds and sequesters pro-apoptotic proteins
- Expression reduced in vulnerable substantia nigra [neurons](/entities/neurons)
Parkin Regulation
- 14-3-3θ binds to parkin and regulates its E3 ligase activity
- Disrupted interaction may contribute to mitophagy defects
- Links mitochondrial dysfunction to protein aggregation
Alzheimer's Disease
In [Alzheimer's disease](/diseases/alzheimers-disease), 14-3-3 proteins show complex involvement[@xing2020][@qureshi2013]:
[Tau](/proteins/tau) Pathology
- 14-3-3θ can bind to hyperphosphorylated tau
- May facilitate tau aggregation or clearance
- Detected in neurofibrillary tangles
Amyloid-β Signaling
- Modulates [amyloid-beta](/proteins/amyloid-beta)-induced toxicity
- Regulates [APP](/entities/app-protein) processing indirectly
- Altered expression in AD brain regions
Synaptic Dysfunction
- 14-3-3θ regulates synaptic plasticity proteins
- Influences [NMDA receptor](/entities/nmda-receptor) trafficking
- May contribute to early synaptic deficits
Amyotrophic Lateral Sclerosis
14-3-3 proteins are implicated in [ALS](/diseases/amyotrophic-lateral-sclerosis) pathogenesis[@brotherton2019]:
- Binding to mutant SOD1 aggregates
- Interaction with [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology
- Motor neuron vulnerability factors
Huntington's Disease
In [Huntington's disease](/diseases/huntingtons)[@zhang2017]:
- Mutant [huntingtin](/proteins/huntingtin) disrupts 14-3-3 function
- Alters subcellular localization
- Contributes to transcriptional dysregulation
Prion Disease
14-3-3θ is a well-established biomarker in [prion diseases](/diseases/creutzfeldt-jakob)[@collins2015]:
- Elevated in cerebrospinal fluid
- Reflects neuronal damage
- Used in clinical diagnosis
Genetic Associations
Polymorphisms
- rs1043981: Missense variant with debated association to PD
- rs2297522: 3'UTR variant influencing expression
- Haplotype structures show population-specific effects[@genetics2019]
Expression Studies
- Increased YWHAQ in PD substantia nigra
- Decreased expression in AD [hippocampus](/brain-regions/hippocampus)
- Cell type-specific alterations in neurodegeneration
Animal Models
Knockout Studies
- Ywhaq knockout mice: Viable with subtle neurological phenotypes
- Synaptic plasticity deficits: Impaired [LTP](/mechanisms/long-term-potentiation) in hippocampal slices
- Increased neuronal apoptosis: Enhanced vulnerability to stress[@che2011]
Transgenic Models
- 14-3-3θ overexpression: Protects against α-synuclein toxicity
- Conditional expression: Reverses some PD-like phenotypes
- Isoform-specific effects: Different isoforms have distinct functions[@zhou2018]
Therapeutic Targeting
Small Molecule Modulators
Therapeutic Strategies
Client-specific targeting: Focus on specific disease-relevant interactions
Peptide-based approaches: Cell-penetrating peptides to modulate interactions
Gene therapy: Modulate expression in target tissues
Combination approaches: Target multiple 14-3-3 interactions simultaneouslyChallenges
- Broad client network creates off-target concerns
- Isoform-selectivity difficult to achieve
- [Blood-brain barrier](/entities/blood-brain-barrier) penetration required
- Therapeutic window must be carefully defined[@cao2021]
Biomarker Potential
Diagnostic Applications
- Cerebrospinal fluid 14-3-3: Established marker for prion disease
- Blood-based detection: Under development for PD and AD
- Pet imaging agents: Not yet available
Disease Progression
- Correlates with clinical measures in PD
- May predict cognitive decline in AD
- Potential for monitoring treatment response
Client-specific Signatures
- Different client patterns may indicate specific pathways activated
- Phospho-14-3-3 signatures under investigation
- Personalized medicine applications possible
Interactions
Protein-Protein Interactions
Post-Translational Modifications
- Phosphorylation: Multiple sites regulate client binding
- Acetylation: Influences dimer stability
- Oxidative modification: Affects function under stress
- Ubiquitination: Targets for degradation[@jetton2019]
Expression and Localization
Brain Distribution
- Neuronal expression: High in pyramidal neurons
- Glial expression: Present in [astrocytes](/entities/astrocytes) and [microglia](/cell-types/microglia-neuroinflammation)
- Regional variation: Highest in hippocampus and [cortex](/brain-regions/cortex)
Subcellular Localization
- Cytoplasmic: Major pool, involved in signaling
- Nuclear: Regulates transcription factors
- Mitochondrial: Imported in response to stress
- Synaptic: Localized to presynaptic terminals
Future Directions
- Development of selective 14-3-3θ modulators
- Understanding isoform-specific functions
- Clinical biomarker validation
- Gene therapy approaches
- Combination with disease-modifying therapies
Related Pages
- [YWHAQ Gene](/genes/ywhaq)
- [14-3-3 Protein Family](/entities/14-3-3-proteins)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [LRRK2 Gene](/genes/lrrk2)
- [Parkin Gene](/genes/parkin)
- [Tau Protein](/proteins/tau)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Lewy Body Pathology](/entities/lewy-bodies)
See Also
- [Parkinson's disease](/diseases/parkinsons-disease)
- [Alzheimer's disease](/diseases/alzheimers-disease)
- [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [TDP-43](/mechanisms/tdp-43-proteinopathy)
- [Huntington's disease](/diseases/huntingtons)
- [prion diseases](/diseases/creutzfeldt-jakob)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Unknown, Aitken, 14-3-3 proteins: a historic overview (2006) (2006)](https://doi.org/10.1016/j.semcancer.2006.04.005)
[Gardino et al., Structural determinants of 14-3-3 client interactions (2009) (2009)](https://doi.org/10.1016/j.tibs.2009.06.005)
[Unknown, Morrison, The 14-3-3 proteins (2009) (2009)](https://doi.org/10.1016/j.tcb.2009.05.004)
[Wang et al., 14-3-3 proteins in Parkinson's disease (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24513008/)
[Xing et al., 14-3-3 proteins in Alzheimer's disease (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32029901/)
[Obsilova et al., 14-3-3 proteins: a family of molecular hubs (2021) (2021)](https://doi.org/10.1016/j.tibs.2021.01.009)
[Yaffe et al., Phosphopeptide recognition by 14-3-3 proteins (1997) (1997)](https://doi.org/10.1016/S0092-8674(00)
[Zhang et al., 14-3-3 and MAPK signaling (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20932476/)
[Luk et al., 14-3-3 in cell cycle control (2010) (2010)](https://doi.org/10.1016/j.semcdb.2010.08.002)
[Masters et al., 14-3-3-mediated apoptosis regulation (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20538036/)
[Dumitriu et al., 14-3-3θ and LRRK2 in PD (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27215564/)
[Wong et al., 14-3-3 proteins in dopaminergic neurons (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25903908/)
[Qureshi et al., 14-3-3 in tauopathies (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24322488/)
[Brotherton et al., 14-3-3 and ALS pathogenesis (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31113287/)
[Zhang et al., 14-3-3 in Huntington's disease (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28065471/)
[Collins et al., Cerebrospinal fluid 14-3-3 in prion disease (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26206856/)
[Unknown, Genetics of Parkinson's Disease Consortium, 14-3-3 genetic associations (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30665862/)
[Che et al., Ywhaq knockout mouse phenotype (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21360190/)
[Zhou et al., 14-3-3 transgenic models of PD (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29526584/)
[Cao et al., Targeting 14-3-3 proteins for therapy (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34002945/)
[Jetton et al., 14-3-3 post-translational modifications (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31151918/)